Latest Stock Pick: Novavax Inc


Matthew Feldman

A vial of the Novavax COVID-19 vaccine.


What Is Novavax

Over the summer, I researched some stocks and found a company called Novavax. Novavax is a biotechnology company located in Gaithersburg, Maryland. The company has recently gained traction after creating a FDA-approved coronavirus vaccine. With the innovation, the company is now worth $18 billion. 


Coronavirus Vaccine History With Novavax

In January 2020, Novavax announced the development of a coronavirus vaccine, named NVX-CoV2373. In March 2020, they announced a collaboration with Emergent BioSolutions for preclinical and early-stage human research on the vaccine candidate. The first human safety studies of the NVX-CoV2373 vaccine started in May 2020, and soon after the company received $1.6 billion from Operation Warp Speed to develop its candidate. In June 2021, Novavax received FDA approval on the NVX-CoV2373 vaccine, which shows 93% efficacy against variants of the coronavirus. Recently in August, Novavax sold 100 million vaccines in Europe, and is now planning to expand international sales.


Why Novavax Is A Worthwhile Investment 

Even though many people in the U.S. are vaccinated, the coronavirus pandemic is far from over. Across the world, there are still nations with too many unvaccinated citizens and too few vaccines. To combat this, Novavax offers easier shipping and storage because their vaccine requires temperatures 2º to 8º C. This temperature requirement is better than the ultra-low temperatures that other vaccine competitors require. 


Novavax is sure to be a worthwhile investment as the company continues to sell its vaccines around the world to vaccinate the remainder ¾ of the world that hasn’t gotten the chance. With vaccines widely needed, Novavax has a lot of profit soon to be made.


*Not a financial advisor. All investment strategies and investments involve risk of loss. Nothing contained in this article should be construed as investment advice. Any reference to an investment’s past or potential performance is not, and should not be construed as, a recommendation or as a guarantee of any specific outcome or profit. The opinions expressed in this article are the author’s own. Harriton Banner does not endorse nor support views, opinions or conclusions drawn in this article and are not responsible or liable for any content, accuracy or quality within the article or for any damage or loss to be caused by and in connection to it.*